Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Factor X Deficiency
Interventions: FACTOR X; Biological
Lead sponsor: Bio Products Laboratory; Other
Eligibility: 12 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
Interventions: high dose rate brachytherapy; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Durvalumab, Radiation Therapy, Tremelimumab; Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 41
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more

Conditions: High Grade Glioma, Glioblastoma
Interventions: BDTX-1535, BDTX-1535 combined with radiation therapy, BDTX-1535 combined with temozolomide and radiation therapy; Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Chandler, Arizona • Phoenix, Arizona

Conditions: Hypertension
Interventions: SMS System, blood pressure control education; Other · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Lung Carcinoma, Metastatic Malignant Neoplasm in the Lung
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anxiety, Loneliness, Depression, Alcohol Use Disorder, Utilization, Health Care
Interventions: Shared Medical Visit; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Refractory Chronic Lymphocytic Leukemia, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: romidepsin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Prostate Cancer
Interventions: Docetaxel, Ketoconazole; Drug
Lead sponsor: Kansas City Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Prone Positioning, High Flow Nasal Cannula, Acute Respiratory Distress Syndrome, Corona Virus Infection
Interventions: high flow nasal cannula (HFNC), Prone positioning (PP); Device · Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Age Related Macular Degeneration
Interventions: Ultrasound examination; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Ofatumumab, Prednisone, Rituximab, Vincristine Sulfate; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Preeclampsia
Interventions: 162mg aspirin dose; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Myelodysplastic Syndromes
Interventions: High-dose ascorbate, Azacitidine; Drug
Lead sponsor: Prajwal Dhakal; Other
Eligibility: 18 Years to 99 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Interventions: Biopsy, Biospecimen Collection, Enfortumab Vedotin, MR Urography, Nephroureterectomy, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
Interventions: LY3300054, Ramucirumab, Abemaciclib, Merestinib, LY3321367; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 3
States / cities: Nashville, Tennessee • Houston, Texas • San Antonio, Texas

Conditions: Prostate Cancer
Interventions: Cross-linked hyaluronan gel; Device
Lead sponsor: Cancer Center of Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Irvine, California

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Trivalent Influenza Vaccine; Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 40 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pregnancy, IUGR, Preeclampsia
Interventions: Collection of myometrial, cord blood, and placental tissue samples; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Dehydration
Interventions: Water, Hydration Education; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 13 Years to 19 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma
Interventions: oncolytic HSV-1716, dexamethasone, therapeutic conventional surgery, laboratory biomarker analysis; Biological · Drug · Procedure + 1 more
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 12 Years to 21 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Influenza
Interventions: Oseltamivir, Peramivir; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Baltimore, Maryland

Conditions: Colorectal Cancer, Pancreatic Cancer
Interventions: filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14; Biological · Procedure · Radiation
Lead sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 3
States / cities: Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania

Conditions: Saphenous Vein Graft Disease
Interventions: Atorvastatin 80 mg daily, Atorvastatin 10 mg daily; Drug
Lead sponsor: Boca Raton Regional Hospital; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Boca Raton, Florida

Search by objective public record fields.

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

SMS System for Patients With Uncontrolled Hypertension

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care

Loneliness and Health Outcomes in the High Need Population

FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia

Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study

Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS

High-Resolution Ultrasound Imaging of the Retina and Choroid for Detection on Age Related Macular Degeneration

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia

Ascorbate in Myelodysplastic Syndrome

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

Effects of High Altitude on AMPK Activation

Efficacy of Education Versus Education Plus Prescribed Fluid Intake on Hydration Status in High School Athletes

Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)